Arylcyclohexylethers of dihydrotetraazabenzoazulenes

A compound of formula I

• wherein
• R1 is a monovalent cyclic aromatic hydrocarbon moiety consisting of a mono- or bicyclic aromatic ring,
• a monovalent 5- or 6-membered aromatic monocyclic or 9- or 10-membered aromatic bicyclic ring containing from one to four ring heteroatoms selected from N, O, or S, the remaining ring atoms being C,
• each unsubstituted or substituted with one or more substituents independently selected from A;
• R2 is H,
• C1-12-alkyl, unsubstituted or substituted with one or more OH, halo, cyano or C1-12-alkoxy,
• —(CH2)q—Ra, wherein Ra is phenyl or 5- or 6-membered heteroaryl, each of which is unsubstituted or substituted with one or more substituents independently selected from A,
• —(CH2)rNRiRii,
• —C(O)—C1-12-alkyl, wherein C1-12-alkyl is unsubstituted or substituted with one or more OH, halo, cyano or C1-12-alkoxy,
• —C(O)(CH2)qOC(O)—C1-12-alkyl,
• —C(O)(CH2)qNRiRii,
• —C(O)O—C1-12-alkyl, wherein alkyl is unsubstituted or substituted with one or more OH, halo, cyano or C1-12-alkoxy,
• —S(O)2—C1-12-alkyl, or
• —S(O)2NRiRii,
• Ri and Rii are each independently H, C1-12-alkyl, or together with the nitrogen to which they are bound form a 3- to 7-membered heterocycloalkyl containing one or two heteroatoms selected from N, O and S, which heterocycloalkyl is unsubstituted or substituted by one or more substituents independently selected from B,
• q is 1, 2, 3 or 4,
• r is 2, 3 or 4,
• A is halo, cyano, OH, C1-7-alkyl, halo-C1-7-alkyl, C1-7-alkoxy, halo-C1-7-alkoxy, hydroxy-C1-7-alkyl.
• B is oxo, halo, OH, C1-7-alkyl or C1-7-alkoxy, and
• R3 is Cl or F,
• or a pharmaceutically acceptable salt thereof.

A pharmaceutical composition comprising a compound of formula I

• wherein
• R1 is aryl or heteroaryl, each of which is unsubstituted or substituted with one or more substituents independently selected from A,
• R2 is H,
• C1-12-alkyl, unsubstituted or substituted with one or more OH, halo, cyano or C1-12-alkoxy,
• —(CH2)q—Ra, wherein Ra is phenyl or 5- or 6-membered heteroaryl, each of which is unsubstituted or substituted with one or more substituents independently selected from A,
• —(CH2)rNRiRii,
• —C(O)—C1-12-alkyl, wherein C1-12-alkyl is unsubstituted or substituted with one or more OH, halo, cyano or C1-12-alkoxy,
• —C(O)(CH2)qOC(O)—C1-12-alkyl,
• —C(O)(CH2)qNRiRii,
• —C(O)O—C1-12-alkyl, wherein alkyl is unsubstituted or substituted with one or more OH, halo, cyano or C1-12-alkoxy,
• —S(O)2—C1-12-alkyl, or
• —S(O)2NRiRii,
• Ri and Rii are each independently H, C1-12-alkyl, or together with the nitrogen to which they are bound form a 3- to 7-membered heterocycloalkyl containing one or two heteroatoms selected from N, O and S, which heterocycloalkyl is unsubstituted or substituted by one or more substituents independently selected from B,
• q is 1, 2, 3 or 4,
• r is 2, 3 or 4,
• A is halo, cyano, OH, C1-7-alkyl, halo-C1-7-alkyl, or C1-7-alkoxy, halo-C1-7-alkoxy, or hydroxy-C1-7-alkyl,
• B is oxo, halo, OH, C1-7-alkyl or C1-7-alkoxy, and
• R3 is Cl or F,
• or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.